Skip to main content

Vertex Pharmaceuticals Inc. (VRTX) Stock

Vertex Pharmaceuticals Inc. Stock Details, Movements and Public Alerts

Stock Details

Vertex Pharmaceuticals Inc. (VRTX), a prominent company in the life sciences sector within the pharmaceutical preparations industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $469.65. Over the past 52 weeks, it has ranged between $377.85 and $519.88. This places the current price at 90.3% of its 52-week high and 24.3% above its 52-week low. Recent trading volume was recorded at 1,176,853. The International Securities Identification Number (ISIN) for this stock is US92532F1003.

Market Cap

$113.32B

52-Week High

$519.88

-9.66% from high

52-Week Low

$377.85

+24.30% from low

Avg Daily Volume

1,176,853

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

24.69

PEG Ratio

0.58

Potentially undervalued

Price to Book

6.87

EV/EBITDA

254.75

EPS (TTM)

-$3.84

Price to Sales

10.21

Beta

0.42

Less volatile than market

How is VRTX valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is VRTX's risk profile compared to the market?
With a beta of 0.42, Vertex Pharmaceuticals Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.87 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-8.91%

Operating Margin

37.20%

Return on Equity

-5.64%

Return on Assets

11.80%

Revenue Growth (YoY)

3.00%

Earnings Growth (YoY)

-40.90%

How profitable and efficient is VRTX's business model?
Vertex Pharmaceuticals Inc. achieves a profit margin of -8.91%, meaning it retains $-8.91 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 37.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -5.64% and ROA at 11.80%, the company achieves moderate returns on invested capital.
What are VRTX's recent growth trends?
Vertex Pharmaceuticals Inc.'s revenue grew by 3.00% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 40.90% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Company Size & Market

Shares Outstanding

256.80M

Book Value/Share

$64.20

Asset Type

Common Stock

What is VRTX's market capitalization and position?
Vertex Pharmaceuticals Inc. has a market capitalization of $113.32B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 256.80M shares outstanding, the company's ownership is relatively concentrated. As a major player in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.
How does VRTX's price compare to its book value?
Vertex Pharmaceuticals Inc.'s book value per share is $64.20, while the current stock price is $469.65, resulting in a price-to-book (P/B) ratio of 7.32. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$499.87

6.43% upside potential

Analyst Recommendations

Strong Buy

4

Buy

14

Hold

14

Sell

1

Strong Sell

1

How reliable are analyst predictions for VRTX?
34 analysts cover VRTX with 53% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $499.87 implies 6.4% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on VRTX?
Current analyst recommendations:4 Strong Buy, 14 Buy, 14 Hold, 1 Sell, 1 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:45 AM

Technical Indicators

What does VRTX's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret VRTX's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for VRTX and get notified when the price changes.

Stay Ahead of the Market with Vertex Pharmaceuticals Inc. Alerts

Set up price alerts for Vertex Pharmaceuticals Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.